Actuate Therapeutics annual return on equity
2025
Actuate Therapeutics Return on Equity (ROE) Growth & History (ACTU)
Actuate Therapeutics's return on equity was −553.75% for fiscal 2025.
View full Actuate Therapeutics company overviewActuate Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −553.75% | — |
Actuate Therapeutics quarterly return on equity
Q4.24
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −203.90% | — |
| Q1 2026 | 2026-03-31 | −96.10% | — |
| Q4 2025 | 2025-12-31 | −48.29% | +187.70 pp |
| Q3 2025 | 2025-09-30 | −130.57% | — |
| Q4 2024 | 2024-12-31 | −236.00% | — |
Actuate Therapeutics return on equity trends
The latest reported quarter, Q2 2026, shows −203.90%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Actuate Therapeutics source filings ↗